**Supplemental table 1.**

**Table 1. Clinical characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Study 1**  **(N=14)** | **Study 2**  **(N=8)** | **Total Sample**  **(N=22)** |
| Age (yr) | 46 (38, 56) | 34 (31, 38) | 40 (34, 50) |
| Male, N (%) | 6 (43%) | 4 (50%) | 10(45%) |
| Race, N (%)  African American  European American  Latino- Non Black  Other | 7 (50%)  5 (36%)  1 (7%)  1 (7%) | 4 (50%)  3 (36%)  0  1 (13%) | 11 (50%)  8 (36%)  1 (5%)  2 (9%) |
| Proteinuria (g/d) | 9.7 (7.9, 12.3) | 9.6 (8.1, 12.2) | 9.6 (7.8, 12.2) |
| eGFR  (mL/min/1.73m2) | 66 (50, 86) | 66 (60, 69) | 66 (50, 86) |
| Blood pressure systolic mmHg | 130 (117, 138) | 115 (111, 128) | 127 (113, 135) |
| Blood pressure  Diastolic mmHg | 72 (67, 81) | 70 (64, 78) | 72 (65, 80) |

**Supplemental Table 2. Summary of efficacy outcomes.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **End of study** | | | **Long term evaluation** | |
|  | **Study 1**  **N= 14** | **Study 2**  **N= 7** | **Total study group**  **N= 21** | **Study 1 & 2**  **dexamethasone only**  **N= 14** | **Total study group**  **N= 19** |
| **Complete remission** | 0 | 0 | 0 | 1 (7%) | 2 (11%) |
| **Partial remission** | 5 | 2 | 7 (33%) | 4 (29%) | 6 (32%) |
| **Limited response** | 2 | 2 | 4 (21%) | 2 (14%) | 2 (11%) |
| **No Response** | 7 | 3 | 10 (48%) | 3 (21%) | 3 (16%) |
| **CKD 4, 5** | - | - | - | 4 (29%) | 6 (32%) |

**Legend.** Shown is the remission status at the end of study and at last evaluation. One subject was lost to follow-up at last evaluation and one patient died from pancreatic cancer. The long-term evaluation was carried out a median 5.3 years after EOS. Fourteen subjects received dexamethasone treatment only (as part of the present study), and five subjects received additional immunosuppressant therapy following completion of the present study.

**Supplemental Table 3.**  **Efficacy outcomes.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Demographics** | | | | **Baseline** | | | **End of study**  **outcome** | | | **Short term follow-up**  **(24 months)** | | | | **Long term evaluation** | | | | |
| **Subject** | **Race** | **Sex** | **Age** | **Serum Albumin** | **CKD-EPI**  **eGFR** | **Urine protein**  **(g/d)** | **CKD-EPI**  **eGFR** | **Urine protein(g/d)** | **Remission** | **Nadir urine protein** | **Remission**  **status** | **Subsequent peak urine protein** | **Relapse from CR or PR** | **Time**  **(yr)** | **IST**  **After**  **EOS** | **CKD-EPI eGFR** | **Urine protein**  **(g/d)** | **Remission** |
| 1 | AA | M | 46 | 3.8 | 64 | 11.0 | 58 | 1.4 | PR | 1.3 | PR | 1.2 | No | 9.8 | - | 50 | 0.3 | CR |
| 2 | A | F | 57 | 2.2 | 51 | 8.4 | 82 | 0.5 | PR | 0.2 | CR | 18.4 | Yes | 9.9 | CSA | 66 | 3.7 | LR |
| 3 | H | M | 41 | 3.2 | 83 | 12.7 | 82 | 3.4 | PR | 3.0 | PR | 3.0 | Yes | 5.3 | - | 59 | 0.9 | PR |
| 4 | AA | F | 30 | 2.8 | 99 | 9.2 | 87 | 4.4 | LR | 3.4 | PR | 7.84 | Yes | 9.1 | - | 73 | 1.2 | PR |
| 5 | AA | M | 34 | 3.7 | 60 | 7.7 | 56 | 10.7 | NR | 4.5 | NR | 4.5 | No | 4.6 | - | 50 | 4.9 | NR |
| 6 | W | M | 45 | 4.0s | 45 | 3.5 | 42 | 3.5 | NR | 6.7 | NR | 6.75 | No | 7.7 | MMF | 6 | 12.2 | CKD 5 |
| 7 | AA | F | 71 | 3.1 | 44 | 4.6 | 36 | 1.7 | PR | 5.1 | NR | 4.84 | Yes | 1.0 | - | 20 | 4.8 | CKD 4 |
| 8 | AA | F | 38 | 1.9 | 99 | 10.2 | 103 | 7.6 | NR | ND | ND | ND | NA | 7.0 | MMF | 69 | 0.8 | PR |
| 9 | AA | F | 40 | 2.2 | 125 | 8.6 | 93 | 3.7 | LR | 2.2 | PR | 0.66 | No | 7.0 | - | 80 | 0.5 | PR |
| 10 | AA | F | 52 | 2.5 | 68 | 13.8 | 51 | 9.3 | NR | ND | ND | ND | NA | 5.8 | - | 9 | 9.5 | CKD 5 |
| 11 | W | M | 56 | 1.7 | 86 | 17.3 | 79 | 23.8 | NR | ND | ND | ND | NA | ND | - | ND | ND | ND |
| 12 | W | M | 62 | 2.6 | 86 | 7.2 | 60 | 6.8 | NR | 7.9 | NR | 9.3 | Yes | 2.9 | - | 45 | 9.3 | NR |
| 13 | W | M | 67 | 2.3 | 42 | 15.6 | 61 | 10.4 | NR | CSA | NA | NA | NA | 5.8 | CSA | 46 | 0.2 | CR |
| 14 | W | F | 49 | 2.5 | 50 | 10.1 | 66 | 1.4 | PR | CSA | NA | NA | NA | 6.0 | CSA | 42 | 0.5 | PR |
| 15 | W | F | 36 | 1.3 | 72 | 12.3 | 75 | 3.8 | LR | 8.1 | LR | 10.7 | No | 3.0 | \* TAC | 80 | 6.0 | LR |
| 16 | W | M | 31 | 1.8 | 101 | 9.5 | 79 | 11.5 | NR | 5.6 | NR | NA | No | ND | - | ND | ND | ND |
| 17 | AA | F | 24 | 1.5 | 66 | 8.5 | 89 | 2.3 | PR | 1.0 | PR | NA | NA | 5.2 | - | 87 | 1.0 | PR |
| 18 | AA | F | 34 | 2.1 | 62 | 12.1 | 51 | 4.6 | LR | 2.5 | PR | NA | Yes | 4.2 | - | 6 | ND | CKD 5 |
| 19 | A | M | 51 | 3.5 | 41 | 5.9 | 39 | 3.6 | NR | 2.5 | PR | 0.9 | No | 5.6 | MMF | 20 | 2.3 | CKD 4 |
| 20 | AA | F | 35 | 1.4 | 58 | 20.8 | 56 | 2.7 | PR | 1.9 | PR | 3.2 | Yes | 3.5 | - | 30 | 2.2 | CKD 4 |
| 21 | AA | M | 31 | 2.4 | 66 | 6.0 | 70 | 4.3 | NR | 2.8 | PR | NA | Yes | 1.0 | - | 70 | 3.8 | NR |

**Supplemental Table 4. Outcomes by FSGS histologic class.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Study 1  N=14 | Study 2  N=8 | Total study group  N= 22 | CR/PR at end of study  N=8 | CR/PR after 24 months of follow-up  N=7 |
| Collapsing variant | 1 | 1 | 2 | 2 | 2 |
| Tip variant | 3 | 0 | 3 | 2 | 2 |
| Cellular variant | 0 | 0 | 0 | 0 | 0 |
| FSGS, not otherwise specified | 9 | 6 | 16 | 4 | 3 |
| Minimal change disease | 0 | 1 | 1 | 0 | 0 |
|  |  |  |  |  |  |

**Legend.** Kidney biopsies from 22 subjects were classified according to histologic variant.  The biopsy from the subject in study 22 that was not included in the efficacy analysis was read as not otherwise specified. There were 3 biopsies not available for review; the original biopsy interpretations were collapsing variant, not otherwise specified, and minimal change disease. The reported complete response (CR) and partial response (PR) in total study were at end of study (8 subjects met remission criteria) and 24 months after end of study (7 subjects met remission criteria).

**Supplemental** **Table 5.** **SF-36 scores of physical health.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Domains** | **Baseline** | **End of Study** | ***P* value** |
|  | N= 20 | N= 19 |  |
| **Physical Function** | 90 (50, 96) | 90 (70, 98) | 0.32 |
| **Role limitations, physical** | 88(19, 100) | 75 (25,100) | 0.80 |
| **Bodily pain** | 74 (60, 100) | 84 (66, 85) | 0.71 |
| **General health perception** | 57 (39, 68) | 60 (40, 67) | 0.81 |
| **Vitality/ energy** | 48 (29, 65) | 60 (43, 70) | 0.06 |
| **Social Functioning** | 75 (60, 91) | 88 (63, 100) | 0.15 |
| **Role limitations, emotional** | 100 (67, 100) | 100 (86, 100) | 0.50 |
| **Mental health** | 82 (63, 88) | 84 (76, 94) | 0.01 |

**Legend**. Presented are the scores, as media and interquartile range for subjects in study 1 and study 2 for the 8 domains of the SF-36 instrument of subject health. Two subjects SF-scores were not done at follow-up evaluation. The P values for the comparison of baseline and end-of-study comparison are given; the only significant change was an improvement in mental health scores.

**Supplemental Figure 1. DEXA Scores.**

****

**Legend.** Shown are the change in DEXA scan values, as T scores, for total femur and spine from baseline to 16 weeks (treatment mid-point) in study 1; baseline to 24 weeks (treatment mid-point) in study 2; and baseline to end of study in study 1 and 2. End of study occurred at 32 weeks for study 1 and at 48 weeks for study 2. None of the changes were significantly different between baseline and the endpoint indicated.